Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP vs TPF induction chemotherapy with concurrent cisplatin chemoradiotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR1800016613Phase 3Recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, docetaxel and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoints: Chemoradiotherapy-related toxicities, Weight and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
gemcitabinecisplatindocetaxelfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR1800016613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016613.